(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Wednesday and Thursday and not separately reported by Alliance News: Read More
GSK PLC - London-based pharmaceutical company - Starts on Wednesday the second tranche of its previously announced GBP2.0 billion share buyback programme. The new tranche, worth up to GBP450.0 million, follows the completion of a first tranche of GBP700.0 million on Tuesday. Merrill Lynch International will run the second tranche, after Citigroup Global Markets Ltd ran the first. It will be completed by September 19. Shares bought will be held in treasury. Read More
(Alliance News) - Stocks were called higher in the UK on Wednesday, as industry spokespeople cautiously welcome Donald Trump's decision to keep tariffs at 25% on British steel and aluminium for now. Read More
(Alliance News) - London's FTSE 100 posted modest gains on Tuesday as US markets rose after encouraging US jobs data, helping offset weak mining stocks and lower growth forecasts from the OECD. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More
(Alliance News) - Stocks were called to open higher on Tuesday, following claims that trade talks between US President Donald Trump and Chinese President Xi Jinping are imminent. Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Stock prices in London opened mixed on Monday, ahead of the UK's manufacturing PMI reading and following the government's announced commitments to defence spending. Read More
(Alliance News) - GSK PLC on Monday announced the US Food & Drug Administration has accepted for review the new drug application for its liver disease treatment, linerixibat. Read More
(Alliance News) - The FTSE 100 outperformed in a mixed day for European equities, after the US Court of Appeals temporarily reinstated Donald Trump's tariffs. Read More
(Alliance News) - GSK PLC on Wednesday said it will stop a late-stage trial early for an investigational oral antibiotic to treat complicated urinary tract infections, or cUTIs, after the treatment showed positive results in an interim analysis. Read More
(Alliance News) - Stock prices in London closed in the red on Friday, following US President Donald Trump's renewed tariff threats against the EU and Apple. Read More
(Alliance News) - GSK PLC on Friday said its drug Blenrep has received a "positive opinion" from the European Medicines Agency's Committee for Medicinal Products for Human Use. Read More
(Alliance News) - European stocks opened higher on Friday, as a cooling of US yields calmed some investor nerves, while improved UK data boosted sterling. Read More
(Alliance News) - GSK PLC on Thursday said the US Food & Drug Administration has approved its asthma drug Nucala as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease, or COPD, who have an eosinophilic phenotype. Read More
(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma. Read More
(Alliance News) - The FTSE 100 pushed higher on Friday, ending the week on a strong note, and now at the level it roughly stood at prior to US President Donald Trump's 'liberation day' tariff melee. Read More
(Alliance News) - London's FTSE 100 outperformed European peers, though a share price fall for oil majors and a host of other shares that went ex-dividend kept a lid on the blue-chip index's progress. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - GSK announced on Wednesday that it has agreed with Boston Pharmaceuticals to buy steatotic liver disease medication efimosfermin alfa. Read More